ClinicalTrials.gg
RecruitingNCT07107334Updated Oct 21, 2026

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

A Phase 2 interventional study of Glucagon-like peptide 1 receptor agonist in Endometrioid Endometrial Adenocarcinoma, sponsored by University of Florida. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by University of Florida · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 21, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 715 studies in Endometrial Neoplasms with a site in United States — 195 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Planned enrollment
483rd of 591
20 · median 60
Started
2026
with 45 others
Phase 2
178 of 715
34 open now
Primary completion
2028-11
later than 218 of 283 live
Registered
647th of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 483rd largest by planned enrollment of the 591 interventional ones that give a count, is one of 46 that started in 2026, is one of 178 in phase 2, reaches primary completion later than 218 of the 283 other live ones, and was the 647th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

195 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

190 more — sign in →

All 195 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are pursuing fertility sparing. GLP-1RA are a class of medications that mimic the natural hormone glucagon-like peptide-1. These medications trigger the pancreas to release insulin which can help lower blood sugar levels and delay gastric emptying. The recent FDA approval of GLP-1RAs has changed the landscape for pharmacotherapy for weight loss. These hormone-based obesity medications are novel and revolutionary in obesity medicine. Liraglutine, semaglutide, and tirzepatide have become exceedingly popular for their effects on weight loss and obesity-related comorbidities. More recently, GLP-1RAs have exhibited risk reduction of various obesity associated cancers, including endometrial cancer but their exact role in prevention and treatment has yet to be measured.

03

Conditions studied

  • Endometrioid Endometrial Adenocarcinoma

Keywords

  • Endometrial cancer
  • endometrial intraepithelial neoplasia
  • endometrial adenocarcinoma
  • Levonorgestrel IUD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years old
  • A pathological diagnosis with in the past 4 months consistent with grade 1 endometrioid endometrial adenocarcinoma or EIN
  • For subjects with a diagnosis of endometrial intraepithelial neoplasia/grade 1 endometrioid endometrial adenocarcinoma prior to enrollment in the study, and with a diagnosis made outside this institution, the diagnostic material originating from outside the study site will undergo in-house pathology review before enrollment acceptance.
  • Performance Status of 0 to 3
  • For those with endometrial cancer, no extrauterine involvement or myometrial invasion by MRI (preferred) or transvaginal ultrasound
  • ≥ 30 kg/m2 and one of the following (per medical record or self-report):

    1. Multiple medical co-morbidities (defined as [ASA] score ≥ 3) at physician discretion
    2. Fertility desire
  • Subject has had appropriate age-related breast examinations and imagining prior to study enrollment, as documented in the medical record or via investigator confirmation.
  • Written obtained from the subject and the subject agrees to comply with all the study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Subjects with grade 2 or 3 endometroid or any non-endometrioid histology (i.e., clear cell, carcinoma, serous)
  • Clinical suspicion of disease as assessed by the treating physician or confirmed metastatic disease based on imaging
  • Subjects with abnormal cervical cytology
  • Subjects who are diagnosed with thyroid cancer, pancreatitis, or multiple endocrine neoplasia syndrome type 2
  • Subjects who are confirmed to be pregnant or breastfeeding
  • History of medullary thyroid cancer
  • Subjects with known current or history of hormonally- sensitive carcinoma (e.g., breast, melanoma)
  • Subjects actively taking GLP-1RA for more than 14 days at time of consent.
  • Subjects with levonorgestrel-releasing intrauterine system placed >45 days prior to study enrollment.
  • Subjects must not have more than one active at the time of enrollment (Subjects with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with safety or efficacy assessment of the study [as determined by the treating physician or approved by the PI] may be included).
  • History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician. This includes, but is not limited to, conditions such as (NYHA) Class IV heart failure.
  • Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Glucagon-like peptide 1 receptor agonist

    Drug: Glucagon-like peptide 1 receptor agonist

Interventions

  • DrugGlucagon-like peptide 1 receptor agonist

    Subjects will receive a glucagon-like peptide 1 receptor agonist (either semaglutide, tirzepatide or liraglutide) by self-injection or orally (semaglutide or orforglipron) for as clinically indicated by the treating physician or until the subject receives clearance for staging hysterectomy or for pregnancy pursuit. The choice of glucagon-like peptide 1 receptor agonist for each subject will be at the treating physician's discretion. Subjects will discontinue the glucagon-like peptide 1 receptor agonist 2 weeks before any elective surgical procedure.

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., OrforglipronStudies of OrforglipronOrforglipron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Time from start of GLP-1RA to clearance of staging hysterectomy

    Determine the time from start of GLP-1RA treatment to clearance for staging hysterectomy in patients with poor surgical candidacy for a hysterectomy.

    Time frame: 12 months

  2. Time from start of GLP-1RA to clearance for pregnancy pursuit

    Determine the time from start of GLP-1RA treatment to clearance for pregnancy pursuit in patients pursuing fertility sparing.

    Time frame: 12 months

  3. Endometrial pathologic response

    Determine the endometrial pathologic response 6 months after beginning GLP-1RA treatment

    Time frame: 6 months after beginning GLP-1RA treatment

  4. Endometrial pathologic response

    Determine the endometrial pathologic response 12 months after beginning GLP-1RA treatment

    Time frame: 12 months after beginning GLP-1RA treatment

Secondary outcomes

  1. Length of surgery

    Determine the length of staging hysterectomy surgery

    Time frame: Intraoperative

  2. Number of nights in hospital

    Determine the number of nights spent in the hospital for staging hysterectomy

    Time frame: 12 months

  3. Postoperative complications

    Determine the postoperative complications following staging hysterectomy

    Time frame: 12 months

  4. Patient-reported quality of life

    Compare patient-reported quality of life, as measured by the EORTC QLQ-C30, v3.0 between baseline and at 6 months after beginning GLP-1RA treatment

    Time frame: 6 months

  5. Patient-reported quality of life

    Compare patient-reported quality of life, as measured by the EORTC QLQ-C30, v3.0 between baseline and at 12 months after beginning GLP-1RA treatment

    Time frame: 12 months

  6. Patient-reported quality of life

    Compare patient-reported quality of life, as measured by the EORTC QLQ-C30, v3.0 between baseline and at end of GLP-1RA treatment

    Time frame: at either clearance for pregnancy pursuit or staging hysterectomy, which will ideally occur by 12 months after beginning study treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2028, 31 months after the start.

Of 109 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 115. This study's planned 31 months is below that.

Counting every sponsor, half of 141 studies reached it within 55 months; a quarter within 37 and three quarters within 115.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Aug 6, 2025
StartActual
Apr 7, 2026
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: p•••@ufl.edu · •••3650→a•••@ufl.edu · •••8457; added c•••@ufl.edu · •••5125. See the current contact
Oct 21, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Florida · Gainesville, United StatesContact p•••@ufl.edu · •••3650→a•••@ufl.edu · •••8457Contact added c•••@ufl.edu · •••5125
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Contact Study contact changed: p•••@ufl.edu · •••3650→a•••@ufl.edu · •••8457; added c•••@ufl.edu · •••5125. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Florida · Gainesville, United StatesContact p•••@ufl.edu · •••3650→a•••@ufl.edu · •••8457Contact added c•••@ufl.edu · •••5125

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07107334
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Apr 7, 2026
Primary completion
Nov 2028 (estimated)
Completion
Nov 2029 (estimated)
Last update
Oct 21, 2026

Study contacts

Amber N Batie
Contact
amberbatie@ufl.edu
(352) 273-8457
Laura J Mallinson
Contact
coppola@ufl.edu
(352) 265-5125
Kaitlin Nicholson, MD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Semaglutide · Tirzepatide · Orforglipron

Start the discussion